Skip to main content

Table 3 Baseline Physician and Practice Characteristics

From: Impact of a protein-based assay that predicts prostate cancer aggressiveness on urologists’ recommendations for active treatment or active surveillance: a randomized clinical utility trial

  Overall Intervention Control Int vs, Control
p-value
  n = 129 n = 67 n = 62  
Age (Average / SD) 50.1 (8.9) 49.0 (8.9) 51.2 (8.9) 0.133
Number of years post-fellowship
 0–5 7.2% 10.2% 3.8% 0.410
 6–10 17.3% 18.1% 16.3%
 11–20 45.1% 47.5% 42.3%
 21+ years 30.5% 24.1% 37.7%
Number of MD’s associated with practice
 1–3 33.9% 34.8% 32.8% 0.816
 4–10 35.5% 33.9% 37.4%
 10+ 30.6% 31.3% 29.8%
 Single Specialty Practice (%) 86.3% 85.7% 87.0%
Practice type (% breakdown)
 Group/Staff 85.9% 82.1% 90.2% 0.410
 IPA 4.6% 4.8% 4.3%
 Mixed 7.9% 10.2% 5.4%
 Network 1.5% 2.9% 0.0%
Practice Ownership (% breakdown)
 Physician-Physician group 89.3% 93.1% 85.1% 0.246
 Hospital 6.3% 4.1% 8.9%
 Community Health Center 3.4% 1.4% 5.7%
 Other 0.9% 1.4% 0.3%
Employed by practice (% Yes) 65.3% 66.7% 63.8% 0.713
Average days worked per week (%)
 4 11.0% 14.3% 7.2% 0.568
 5+ 89.0% 85.7% 92.8%
On-site robotic surgery capability (%) 55.5% 51.9% 59.4% 0.364
Number of urology patients seen in 1 week
  < 50 1.6% 1.4% 1.9% 0.861
 51–100 49.6% 48.9% 50.4%
  > 100 48.7% 49.6% 47.7%
Number of prostate cancer patients seen in 1 week
 0–20 58.3% 47.3% 70.8% 0.005
  > 20 41.7% 52.7% 29.2%
Proportion of all patients covered by (sd)
 Medicare 47.6 (11.6) 48.4 (11.8) 46.7 (11.5) 0.379
 Commercial 41.3(13.3) 40.3 (13.0) 42.5 (13.6) 0.316
 Medicaid 6.1(6.4) 6.1 (5.9) 6.2 (6.9) 0.966
 Self-pay 3.7 (4.0) 3.7 (3.8) 3.7 (4.3) 0.989